Gynecologic Oncology

The accelerated approval of the tissue factor–directed antibody and microtubule inhibitor tisotumab vedotin-tftv bolsters the treatment portfolio for patients with recurrent metastatic cervical cancer.

Focusing on locally advanced cervical cancer, experts elucidate the role of surgery and standard of care therapy.

The panel reflects on the current, optimal use of biomarker testing to guide the management of cervical cancer.

The immuno-oncology company Agenus has made the decision to withdraw its biologic license application for the use of the PD-1 inhibitor balstilimab in patients with recurrent or metastatic cervical cancer who experienced disease progression on, or after, chemotherapy.

A comprehensive review of the current paradigm for HPV vaccination and screening to prevent cervical cancer.

Experts provide a brief overview of cervical cancer, focusing on the driving biology and FIGO staging system.

Inguinofemoral radiotherapy could potentially spare patients with vulvar cancer and sentinel node micrometastases from the morbidity of a lymphadenectomy.

The FDA has approved pembrolizumab for use in combination with chemotherapy, with or without bevacizumab, in patients with persistent, recurrent or metastatic cervical cancer whose tumors have a PD-L1 combined positive score of 1 or higher, as determined by an FDA-approved test.

David M. O'Malley, MD, discusses the rationale to evaluate the combination of balstilimab and zalifrelimab in cervical cancer.

R. Wendel Naumann, MD, discusses the evolution of immunotherapy in endometrial cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses the practice-changing data from KEYNOTE-826 examining pembrolizumab plus chemotherapy with or without bevacizumab and next steps for research in recurrent or metastatic cervical cancer.

Floor J. Backes, MD, discusses challenges regarding staging and treatment locations in ovarian germ cell tumors.

The FDA has granted priority review to a supplemental biologics license application for the use of cemiplimab-rwlc in the treatment of patients with recurrent or metastatic cervical cancer whose disease progressed on, or after, chemotherapy.

Dr. Monk discusses the significance of the FDA approval of tisotumab vedotin and notable research that was presented at the 2021 ESMO Congress in cervical cancer.

Robert L. Coleman, MD, FACOG, FACS, discusses the FDA approval of tisotumab vedotin in recurrent or metastatic cervical cancer.

The FDA has granted an accelerated approval to tisotumab vedotin for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab exhibited impressive response rates, duration of response, and overall survival in patients with previously treated recurrent/metastatic cervical cancer.

Tisotumab vedotin elicited significant responses without prohibitive toxicity in combination with carboplatin as frontline therapy, as well as in combination with pembrolizumab as second- or third-line therapy in patients with recurrent or metastatic cervical cancer.

The addition of pembrolizumab to chemotherapy with or without bevacizumab significantly improved survival and response rates in patients with persistent, recurrent, or metastatic cervical cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses outcomes with pembrolizumab plus chemotherapy in patients with recurrent or metastatic cervical cancer, as reported in the phase 3 KEYNOTE-826 trial.

Rechallenge with maintenance olaparib following response to platinum-based chemotherapy significantly improved progression-free survival in heavily pretreated patients with relapsed ovarian cancer, irrespective of BRCA status, according to results of the phase 3 OReO/ENGOT Ov-38 study.

Patients with endometrial cancer who had a high tumor mutational burden experienced high responses to single-agent dostarlimab-gxly, irrespective of mismatch repair or microsatellite stability status.

The 2021 ESMO Congress, held as a virtual format for the second consecutive year, is fast approaching and isn’t holding back in terms of pivotal data across malignancies, especially in breast cancer and gynecologic cancers.

Treatment with the antibody-drug conjugate tisotumab vedotin in combination with bevacizumab, pembrolizumab, or carboplatin was tolerable and elicited encouraging preliminary antitumor activity in patients with recurrent or metastatic cervical cancer.

The combination of pembrolizumab and lenvatinib led to a statistically significant improvement in progression-free survival and overall survival in patients with mismatch repair deficient advanced endometrial cancer following platinum-based chemotherapy.